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fibroblasts. These should be able to continu-
ally remodel the valve matrix and produce
its components (eg, glycosaminoglycans)
with very high turnover.
On this basis, this work is a great con-
tribution in the complex field of engineered
tissue valves, and the announcement is
impressive because it should be able to
offer a different and easier way to reseed
valves before implantation. The authors are
congratulated for their current achievements
and should be encouraged to validate their
results in other in vivo models.
Luca Dainese, MD
Fabio Barili, MD
Paolo Biglioli, MD
Department of Cardiac Surgery
University of Milan
Centro Cardiologico Monzino IRCCS
Milan, Italy
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We thank Dr Dainese for this comment.
Several groups have demonstrated that in
vitro seeding of cells on artificial scaffolds
or on natural matrices in a biomimetic envi-
ronment succeeded in the generation of
functional tissue-engineered heart valves.1,2
More recently, Yacoub3 has said in an inter-
view about mesenchymal stem cells that ‘‘if
you subject these cells, in a 3 dimensional
matrix, to programmes of conditioning us-
ing cyclic pressure of a predefined nature,
they change their phenotype to one that is
very similar to valve tissue.’’ Yacoub and
his team still believe that the future of the
tissue-engineered heart valve is dependant
of an in vitro seeding in a bioreactor. To
our knowledge, for the first time in this
field, our work4 suggests that direct injec-
tion of mesenchymal stem cells seems to
induce almost physiologic recolonization
of valvular matrix under physiologic shear
stress. Re-endothelialization of a decellular-
ized xenogeneic matrix can be obtained
in vivo without the cumbersome step of
bioreactor recellularization. This has the ev-
ident advantage of simplifying the recellula-
rization procedure and guaranteeing that
recolonizing cells will stand the actual
high shear conditions of a cardiac valve.
However, we have to underline the evident
limits of our work. First, we do not knowovascular Surgery c May 2008at the present time whether the recolonizing
cells directly derive from the injected cells
or from autologous cells migrating from
blood or neighboring tissue. Second, as sug-
gested by Dainese et al, a longer follow-up
period is mandatory and should be pro-
longed for more than 1 year to confirm our
results.
Andre´ Vincentelli, MD, PhDa,b
Francis Juthier, MDa,b
Brigitte Jude, MD, PhDa,b
Centre Hospitalier Re´gionala
Universitaire de Lille
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